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Abstract
Probiotics are defined as live micro-organisms, which when administered in adequate amounts, confer health
benefits on the host. Scientists have isolated various strains of Lactobacilli from human milk (such as Lactobacillus
fermentum and Lactobacillus salivarius), and the presence of these organisms is thought to be protective against
breast infections, or mastitis.
Trials of probiotics for treating mastitis in dairy cows have had mixed results: some successful and others unsuccessful.
To date, only one trial of probiotics to treat mastitis in women and one trial to prevent mastitis have been published.
Although trials of probiotics to prevent mastitis in breastfeeding women are still in progress, health professionals in
Australia are receiving marketing of these products.
High quality randomised controlled trials are needed to assess the effectiveness of probiotics for the prevention and/or
treatment of mastitis.
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Background
Human microbiome and probiotics
Over 100 trillion microbes live within our bodies (ten-
fold greater than there are host cells), and they are vital
in maintaining our health [1]. The recent surge in re-
search about the human microbiome has demonstrated
the huge variability of organisms living on and within
the human body. Concerns about the way that the hu-
man microbiome may be negatively affected by modern
life – the direct relationship between courses of antibi-
otics in childhood and the risk of inflammatory bowel
disease, for example [2] – have led to investigations into
the role of “good bacteria” or probiotics to reduce our
vulnerability to pathogenic organisms [3].
In the past, human milk was considered a sterile fluid,
and any organisms identified in milk were considered
skin contaminants [4]. Now we understand that mothers’
milk contains a vast array of organisms, although the
roles of these organisms have yet to be clarified.
Probiotics are defined as live micro-organisms, which
when administered in adequate amounts, confer health
benefits on the host [5]. A pertinent example is the use
of probiotics in very low birth weight preterm infants to
reduce morbidity. In a large randomised blinded con-
trolled Australian study using a probiotic mixture (Bifi-
dobacterium longum subsp. infantis BB-02, Streptococcus
thermophilus TH-4 and B. animalis subsp. lactis BB-12)
fed orally until term corrected age or discharge from
hospital, to infants <32 weeks gestation and <1500 gm
birth weight, an absolute reduction in necrotising en-
terocolitis (NEC) of 54 % was shown [6, 7]. This has
changed practice in neonatal nurseries as a cheap and
safe intervention [7]. Yet in a very similar, large rando-
mised controlled trial in premature babies in the United
Kingdom which used a different probiotic (Bifidobacterium
breve BBG-001), no effect was reported [8].
Since probiotic activity is not just species-specific, but
strain-specific, the identity of the micro-organisms used
in probiotic products needs to be confirmed using mo-
lecular techniques to ensure safety and efficacy [9]. Fur-
thermore reports of several instances where the identify
of micro-organisms isolated from probiotic products dif-
fered from the information on the product label has
raised concerns about documented health benefits and
safety of these products [9].
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Lactobacillus organisms have been shown to reduce
serious infections in extremely preterm infants [10], and
can reduce the risk of childhood eczema [11].
Bacteria in human milk considered to be beneficial for
health – the “good bacteria” – may play a role in redu-
cing the risk of maternal breast infection (mastitis), as
well as providing the infant with a source of healthy mi-
crobes along with their nutrition. From among the sev-
eral hundred species in human milk [4, 12], scientists
have isolated particular species of Lactobacillus from hu-
man milk to study their effect on mothers and babies
[13–16]. The effects of these Lactobacilli are strain-
specific: for example, Lactobacillus fermentum
CECT5716 has an immunostimulatory effect, in contrast
to the antiflammatory effects of Lactobacillus salivarius
CECT5713 [17].
Bacteria from women’s gastrointestinal tract are
thought to travel to the mammary gland via an endogen-
ous route, the enteromammary pathway, via dendritic
cells penetrating the gut epithelium and picking up
organisms, then spreading via the mucosal associated
lymphoid system to the lactating mammary glands [18, 19].
Mothers who ingest Lactobacillus spp supplements have
had the same organisms isolated from their milk and from
their infants’ faeces [14, 15, 20]. Even if maternal ingestion
only occurred during pregnancy, infants have been shown
to be colonised by the same strain in their faecal samples
up to 24 months of age [21].
Probiotics and mastitis
Trials of probiotics for treating mastitis in dairy cows
have had mixed results: some successful [22] and others
unsuccessful [23]. At the local level, an intramammary
infusion of Lactobacillus lactis, a food-grade bacterium,
led to a large up-regulation of cytokines and chemokines
(“a massive immune response”) [24] and neutrophils
[25] capable of eliminating mastitis pathogens [24, 26].
In breastfeeding women, early mastitis can be man-
aged by improving milk drainage from the breast, mas-
sage and applying cold packs to reduce the swelling [27].
When women are acutely ill with fever, and the red,
painful, swollen area of the breast persists for more than
24 h, antibiotics are usually recommended [27, 28]. The
organism most commonly isolated in infective mastitis is
Staphylococcus aureus (S. aureus), and therefore anti-
staphylococcal antibiotics are the mainstay of treatment
(e.g., flucloxacillin) [29]. About 20 % of breastfeeding
women experience at least one episode of mastitis, and
3 % of these women develop a breast abscess [30]. This
is a painful collection of pus within the breast that re-
quires drainage, usually via aspiration under ultrasound
guidance [31].
Families and their health professionals are wary about
using medicines during lactation [32], and even though an
antibiotic such as flucloxacillin is compatible with breast-
feeding [33], an alternative treatment would be welcome.
One trial in Spain set out to compare Lactobacillus
spp probiotics with antibiotics for women with mastitis
[15]. The published paper describes the results at day 21,
and concludes that women receiving Lactobacillus fer-
mentum or Lactobacillus salivarius had less pain and
risk of recurrence of mastitis than women in the anti-
biotic arm of the trial [15]. However, the trial registry in-
dicates that data were collected on days 7, 14 and 28 –
not day 21 [34]; yet only data from one follow-up time-
point (‘day 21’) are reported in the published paper [15].
Anyone suffering with mastitis would expect improve-
ment by day 7, not three weeks later – so why was this
information omitted? Furthermore, although the paper
describes the trial as a blinded randomised controlled
trial, the registry information explains that allocation
was “non-randomised’ and women’s own doctors pre-
scribed the antibiotics; thus the women and the clini-
cians were not blinded to the treatment arm. The
women received a range of antibiotics: amoxycillin,
amoxicillin-clavulanic acid, cotrimoxazole, erythromycin
and cloxacillin – and many of these are well recognised
as unsuitable for the treatment of mastitis, since S. aur-
eus is commonly resistant to some of these antibiotics
(amoxycillin, cotrimoxazole, erythromycin) [29]. Poor
outcomes following inappropriate antibiotics is not sur-
prising. At follow-up, the symptom reported is ‘breast
pain’ which is only one of the indicators of mastitis (the
triad includes lump and redness, as well as fever or ‘flu-
like symptoms). In the trial, women who received antibi-
otics were more likely to report breast pain at day 21,
but some of these women may have had symptoms of
candida infection, a common sequelae to antibiotics in
breastfeeding women [35].
Thus, there are seemingly many problems with the
trial by Arroyo and colleagues [15, 36], and clinicians
have been waiting since 2010 to hear about new trials
with fewer methodological issues.
Considering whether probiotics could prevent episodes
of mastitis, there is only emerging evidence. A recent
paper reports on a trial to prevent mastitis using Lacto-
bacillus salivarus PS2 – a different strain to the previous
study – administered in late pregnancy to women with a
past history of lactational mastitis [37]. The Clinical Tri-
als Registry states the primary outcome for this RCT is:
‘Evidence of clinical mastitis confirmed by microbio-
logical cultures and somatic cell counts [Time Frame:
Weekly during the first 6 months after birth]’, yet the au-
thors report data only to three months in this publica-
tion, and do not provide the somatic cell count data
[37]. In clinical practice, mastitis is confirmed by the
presence of breast and systemic signs and symptoms,
and microbial quantitation is uncommonly used to
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confirm mastitis in breastfeeding women [27, 35]. In
addition, the authors do not provide the difference in
the incidence of mastitis used to calculate their sample
size (either in the publication or the Clinical Trials
Registry). The authors classified mastitis episodes as
‘acute mastitis’ (breast and systemic symptoms) and
‘subacute mastitis’ (breast inflammation only). The terms
‘acute’ and ‘subacute’ mastitis seem to be adopted from
bovine mastitis research, and are rarely used to describe
human lactational mastitis. Clinicians assessing a woman
with localised breast inflammation would diagnosis this
as a blocked duct rather than mastitis [38], and would
rarely prescribe an antibiotic.
The authors state that milk samples were collected
from women who did not report mastitis (‘healthy’ par-
ticipants) between 91 and 100 days postpartum (n = 41
in the treatment arm; n = 23 in the placebo arm). Total
bacterial counts were conducted on these samples. A
statistically significant difference in mean bacterial
counts was reported in healthy participants from the
treatment arm compared to the placebo arm. This differ-
ence is reported as 0.19 log10 CFU/ml, which equates to
1.5 CFU/ml. Although this is significant statistically, we
question the clinical significance of this finding and why
this result was reported? Are the authors suggesting that
L. salivarius PS2 inhibited the growth of other bacteria
(potentially pathogenic)? If this is the case, would a dif-
ference of less than 2 CFU/ml be clinically significant?
The results of this prevention trial provide evidence of
efficacy of this particular strain of L. salivarius – not
currently on the market –for this group of women with
a prior history of mastitis. Women in the probiotic
group were less likely to experience acute mastitis (3/55;
6 %) than women in the placebo group (7/53; 13 %) in
the first three months postpartum [37]. Information
available in international trial registries indicate that
three other trials are underway to assess the effectiveness
of two strains of Lactobacillus in preventing mastitis in
breastfeeding women [39–41].
Despite the paucity of completed trials, companies are
actively marketing probiotics for both the treatment and
prevention of mastitis in Australia.
A media release dated 8 September 2015 was enti-
tled “Probiotics provide alternative to antibiotics for
treatment of mastitis during lactation”. The media re-
lease was linked to a seminar for medical profes-
sionals held in Brisbane. Similar seminars have been
held in Melbourne and Sydney, and all have been
sponsored by Danone Nutricia. The media release
claims that studies have shown that women treated
with Lactobacillus salivarius “improved more quickly
and had lower recurrence of mastitis than those
treated with antibiotics”. The only reference cited is
the paper by Arroyo et al. [15].
Since August 2015, a full page advertisement for the
Nutricia probiotic product, “Mastitis relief”, has been
appearing regularly in Medical Observer, a medical
magazine for Australian general practitioners. The text
says “Used at the first sign of mastitis, new Profutura
Mastitis relief with Probiotic LSS may help relieve or re-
duce breast pain…” The only evidence provided is the
same study cited from Spain [15].
Health professionals reading this advertisement would
assume that there is strong evidence to support these
health claims. In Australia, the Therapeutic Goods Ad-
ministration (TGA) has strict regulations about the
wording of claims about health and medical conditions.
As we have demonstrated, mastitis is a common and po-
tentially serious problem for new mothers, so it would
seem that the TGA must have more evidence than is
available in the published literature.
According to the TGA website, Nutricia received an
exemption for this health claim.
Another company is also heavily marketing a probiotic
product, Qiara (containing Lactobacillus fermentum
CECT5716), at breastfeeding conferences and to health
professionals, including maternal and child health nurses
(email to LHA, August 2015).
Given the problematic nature of the Arroyo et al. trial
[15], and the unfinished status of current trials, it is re-
markable that these suppliers are already marketing their
products as an effective treatment for mastitis. Indeed,
doing so could even be considered as misleading or
deceptive conduct.
The regulatory regimen governing health claims made
in such advertisements is somewhat complex. In
Australia, the TGA enforces strict regulations about the
wording of claims about health and medical conditions
in advertisements [42, 43]. However, most of these rules
do not apply to advertisements directed exclusively to
medical practitioners or nurses [42, 43].
What does still apply, is general consumer protection
law; and the particular part of consumer protection law
that prohibits misleading and deceptive conduct applies
regardless of the fact that it is medical practitioners being
advertised to, rather than the general public [44]. Cases in-
volving this law’s predecessor (in the Trade Practices Act
1974 (Cth)) confirm that advertising of medication in
trade journals – such as publications aimed at doctors or
pharmacists – can be misleading or deceptive if the pre-
cise wording of the advertisement does not reflect the
methodology of the particular study which is cited [45]. In
this situation, relying on one problematic study of probio-
tics as a treatment for mastitis [15] to market probiotics
for use as both a treatment and a preventative oversteps
the scientific evidence available to date.
Consumer protection law also provides that a predic-
tion or representation about the future is misleading if
Amir et al. International Breastfeeding Journal  (2016) 11:19 Page 3 of 5
there are no reasonable grounds for making it [46]. Of
course, using broad language in advertisements – that
probiotics may produce certain outcomes – is not tanta-
mount to making guarantees as to the product’s efficacy
for any particular user. But even a statement that is liter-
ally true can be misleading, including in circumstances
where the whole truth could easily have been learned
upon inquiry [47]. Courts have recognised that ‘in some
circumstances it is necessary to take account of the steps
that a person affected by conduct might reasonably be
expected to take in order to determine whether the con-
duct is misleading or deceptive’ [48]. Given that most
medical professionals would not respond to the current
advertisements by obtaining and reading the cited study
[15], including the citation in those advertisements may
be seen as (wrongly) implying that the claims in the
advertisement rest on more solid evidential ground.
More generally, courts have commented that if there
is no scientific foundation for a statement, this may be
sufficient proof that the statement is misleading [49].
Thus, even where all relevant statutory approvals have
been granted for an advertising campaign for a particular
product [50], advertisements can be misleading if their
claims are not supported by scientific evidence [51]. This
is so regardless of the advertised product’s likelihood of
causing any harm to consumers [51]. As the Australian
Consumer Law imposes strict liability, it is also irrele-
vant that a person engaging in misleading and deceptive
conduct did so unintentionally or unknowingly [52, 53].
Thus, even while these suppliers are taking care to com-
ply with the regulatory framework arising from the
Therapeutic Goods Act, it appears that they may never-
theless be unwittingly making misleading statements, or
implications, in their advertisements.
We conclude with comments from Professor Martin
Blaser, the Past President of the Infectious Diseases Soci-
ety of America and eminent New York microbiome re-
searcher who said "… I'm generally skeptical about the
many claims surrounding all the probiotics crowded on
our grocery store shelves, pharmacies, and health-food
stores. They are almost completely untested” [54] (p.
210). He went on to say: "We won't know if these prod-
ucts are doing any more good than placebos until we
conduct blinded clinical trials…Unfortunately few rigor-
ous trials of this nature have been carried out… But few
of the well-conducted trials that have been performed
show efficacy" [54] (p. 211).
Conclusions
High quality randomised controlled trials are needed to
assess the effectiveness of probiotics for the prevention
and treatment of mastitis. Each strain of bacteria needs
to be tested individually, as efficacy is not only species
specific but strain-specific. The risk of safety concerns is
low, but every probiotic needs to be assessed for safety,
as well as efficacy [55]. Importantly, women may miss
out on more effective treatments – and waste their
money – unless each of the marketed probiotics is
shown to be effective in reducing and treating mastitis.
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